34LA Stock Overview
Operates as a clinical-stage biopharmaceutical company. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Alpine Immune Sciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$59.00 |
| 52 Week High | US$61.00 |
| 52 Week Low | US$7.95 |
| Beta | 0.97 |
| 1 Month Change | -1.67% |
| 3 Month Change | 109.22% |
| 1 Year Change | 582.08% |
| 3 Year Change | 387.60% |
| 5 Year Change | 835.32% |
| Change since IPO | 719.33% |
Recent News & Updates
Recent updates
Shareholder Returns
| 34LA | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -0.8% | 3.1% | 0.5% |
| 1Y | 582.1% | -13.8% | 7.2% |
Return vs Industry: 34LA exceeded the German Biotechs industry which returned -25.7% over the past year.
Return vs Market: 34LA exceeded the German Market which returned 4.3% over the past year.
Price Volatility
| 34LA volatility | |
|---|---|
| 34LA Average Weekly Movement | 22.6% |
| Biotechs Industry Average Movement | 7.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.7% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 34LA's share price has been volatile over the past 3 months.
Volatility Over Time: 34LA's weekly volatility has increased from 17% to 23% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 142 | Mitch Gold | www.alpineimmunesciences.com |
Alpine Immune Sciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company’s product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus.
Alpine Immune Sciences, Inc. Fundamentals Summary
| 34LA fundamental statistics | |
|---|---|
| Market cap | €4.10b |
| Earnings (TTM) | -€33.88m |
| Revenue (TTM) | €51.99m |
78.9x
P/S Ratio-121.0x
P/E RatioIs 34LA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 34LA income statement (TTM) | |
|---|---|
| Revenue | US$56.52m |
| Cost of Revenue | US$83.78m |
| Gross Profit | -US$27.26m |
| Other Expenses | US$9.58m |
| Earnings | -US$36.84m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.54 |
| Gross Margin | -48.23% |
| Net Profit Margin | -65.17% |
| Debt/Equity Ratio | 0% |
How did 34LA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/05/20 05:50 |
| End of Day Share Price | 2024/05/20 00:00 |
| Earnings | 2024/03/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Alpine Immune Sciences, Inc. is covered by 14 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gao Yi Chen | Berenberg |
| Vamil Divan | Guggenheim Securities, LLC |
| Joseph Pantginis | H.C. Wainwright & Co. |